CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $5.06B, above the global median of $1.15B
- FinancialsAltman Z-Score 12.47: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.31%Below 5Y avg (0.32%)
Annual Rate
INR 6.00Paid annual
Payout Ratio
3.9%Sustainable
Last Ex-Dividend
Aug 7, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
484.69BINR5.06B · vs all stocks (USD)
Trailing P/E
36.91xRevenue (TTM)
101.26BINR1.06B · vs all stocks (USD)
Profit Margin
12.93%Beta
0.0350xvs all stocks
52-Week Change
36.48%vs all stocks
Market Capitalization
484.69BINR5.06B · vs all stocks (USD)
Enterprise Value
493.86BINR5.16B · vs all stocks (USD)
Trailing P/E
36.91xForward P/E
27.09xPrice to Sales (TTM)
4.77xPrice to Book (MRQ)
5.99xEnterprise to Revenue
4.88xEnterprise to EBITDA
21.90xGross Margin
71.04%Profit Margin
12.93%Operating Margin
20.04%Return on Assets (TTM)
9.22%Return on Equity (TTM)
11.98%Revenue (TTM)
101.26BINR1.06B · vs all stocks (USD)
Revenue per Share (TTM)
399.16INRUpdated Aug 21, 2026Quarterly Revenue Growth
20.80%Gross Profit (TTM)
68.59BINR716.69M · vs all stocks (USD)
EBITDA (TTM)
21.53BINR224.97M · vs all stocks (USD)
Net Income (TTM)
13.10BINR136.86M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
72.30%Operating Cash Flow (TTM)
11.42BINR119.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
11.41BINR119.24M · vs all stocks (USD)
Trailing Annual Dividend Rate
6.00INRUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.31%vs all stocks
5-Year Average Dividend Yield
0.32%vs all stocks
Payout Ratio
3.87%Minority Interest (Equity)
14.60BINRFY2026 · Mar 31, 2026Revenue
95.63BINRFY2026 · Mar 31, 2026Cost of Goods Sold
29.80BINRFY2026 · Mar 31, 2026Gross Profit
65.82BINRFY2026 · Mar 31, 2026Operating Income
16.30BINR170.34M · vs all stocks (USD)
Pre-tax Income
15.73BINRFY2026 · Mar 31, 2026Income Tax Expense
3.81BINRFY2026 · Mar 31, 2026Net Income
11.84BINRFY2026 · Mar 31, 2026EBIT
16.48BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
20.70BINRFY2026 · Mar 31, 2026Research & Development
1.17BINRFY2026 · Mar 31, 2026Selling, General & Administrative
10.67BINRFY2026 · Mar 31, 2026Other Operating Expenses
11.22BINRFY2026 · Mar 31, 2026Non-operating Interest Income
317.20MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
757.30MINRFY2026 · Mar 31, 2026EPS (Basic)
44.98INRFY2026 · Mar 31, 2026EPS (Diluted)
44.98INRFY2026 · Mar 31, 2026Basic Shares Outstanding
253.70MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
253.70MSharesFY2026 · Mar 31, 2026Minority Interests (P&L)
-426.60MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
14.43BINRFY2026 · Mar 31, 2026Free Cash Flow
7.87BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
10.66BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
15.73BINRFY2026 · Mar 31, 2026Stock-based Compensation
8.10MINRFY2026 · Mar 31, 2026Other Non-cash Items
1.02BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-489.10MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-1.83BINRFY2026 · Mar 31, 2026Capital Expenditures
-6.56BINRFY2026 · Mar 31, 2026Net Acquisitions
0.00INRFY2026 · Mar 31, 2026Purchase of Investments
0.00INRFY2026 · Mar 31, 2026Sale of Investments
553.10MINRFY2026 · Mar 31, 2026Other Investing Activity
3.39BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-2.62BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
0.00INRFY2026 · Mar 31, 2026Long-term Debt Payments
-5.25BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-777.60MINRFY2026 · Mar 31, 2026Common Dividends Paid
-524.10MINRFY2026 · Mar 31, 2026Other Financing Charges
-10.00MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-6.56BINRFY2026 · Mar 31, 2026Shares Outstanding
253.70MSharesUpdated Aug 21, 2026Float Shares
139.31MSharesUpdated Aug 21, 2026% Held by Insiders
45.06%vs all stocks
% Held by Institutions
45.47%vs all stocks
Total Cash (MRQ)
11.96BINR124.93M · vs all stocks (USD)
Total Cash per Share (MRQ)
47.13INRUpdated Aug 21, 2026Total Debt (MRQ)
8.09BINR84.51M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0849xCurrent Ratio (MRQ)
2.76xBook Value per Share (MRQ)
317.84INRUpdated Aug 21, 2026Total Assets
123.70BINR1.29B · vs all stocks (USD)
Total Current Assets
63.77BINRFY2026 · Mar 31, 2026Total Liabilities
28.46BINRFY2026 · Mar 31, 2026Total Non-current Assets
59.93BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
5.39BINRFY2026 · Mar 31, 2026Total Current Liabilities
23.07BINRFY2026 · Mar 31, 2026Cash
1.86BINRFY2026 · Mar 31, 2026Cash Equivalents
2.51BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
4.37BINRFY2026 · Mar 31, 2026Other Short-term Investments
7.58BINRFY2026 · Mar 31, 2026Accounts Receivable
20.14BINRFY2026 · Mar 31, 2026Inventory
27.31BINRFY2026 · Mar 31, 2026Accounts Payable
9.40BINRFY2026 · Mar 31, 2026Short-term Debt
6.13BINRFY2026 · Mar 31, 2026Other Current Liabilities
874.60MINRFY2026 · Mar 31, 2026Long-term Debt
1.96BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
4.20MINRFY2026 · Mar 31, 2026Common Stock (Book)
253.70MINRFY2026 · Mar 31, 2026Retained Earnings
66.28BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
95.24BINR995.17M · vs all stocks (USD)
52-Week Low
1.25KINRUpdated Aug 21, 202652-Week High
1.95KINRUpdated Aug 21, 202652-Week Change
36.48%vs all stocks
Beta
0.0350xvs all stocks
50-Day MA
1.73KINRUpdated Aug 21, 2026200-Day MA
1.55KINRUpdated Aug 21, 2026Avg 10-Day Volume
92.09KSharesUpdated Aug 21, 2026Avg 30-Day Volume
58.11KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
51.59INRUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.47: safe zoneNotable
Altman Z-Score: 12.47
High earnings qualityNotable
Earnings Quality Score: 0.65
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $5.06B, above the global median of $1.15BNotable
Market cap (USD): 5,064,517,561.476Global Median: 1,146,734,693.424
Revenue is $1.06B, above the global median of $520.53MNotable
Revenue (USD): 1,058,107,525.3Global Median: 520,528,949.311
Levered free cash flow is $119.24M, above the global median of $16.24MNotable
Levered free cash flow (USD): 119,235,628.8Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Changchun High-Tech Industry Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Dong-E-E-JiaoCo Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sk Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Travere Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Industria de Diseño Textil, S.A.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income Growth
McDonald's Holdings Co., Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income Growth
GnCenergy Co., Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income Growth